Pitney Bowes Inc., operates as a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to small businesses, large enterprises, and government entities around the world. It operates through SendTech Solutions and Presort Services segments. The SendTech Solutions segment provides physical and digital shipping and mailing technology solutions, and other applications for sending, tracking and receiving of letters, parcels and flats, supplies, and maintenance services, as well as financing alternatives to finance equipment and product purchases. The Presort Services segment offers mail sortation services, which allow clients to qualify volumes of first-class mail, marketing mail, marketing mail flats, and bound printed matter for postal workshare discounts. It markets its products, solutions, and services through direct and inside sales force, global and regional partner channels, direct mailings, and digital channels. The company was formerly known as Pitney Bowes Postage Meter Company. Pitney Bowes Inc. was incorporated in 1920 and is headquartered in Stamford, Connecticut.

Pitney Bowes Inc.

Pitney Bowes ( ($PBI) ) has provided an announcement. On May 18, 2026, Pitney Bowes amended its credit agreement, extending the maturities of its $...

Pitney Bowes Extends Credit Facilities, Tightens Covenants

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has called a General Meeting of shareholders t...

Paradigm Biopharmaceuticals sets June in‑person shareholder meeting with digital proxy push

Pitney Bowes (($PBI)) has held its Q1 earnings call. Read on for the main highlights of the call. Pitney Bowes struck an upbeat tone on its latest ...

Pitney Bowes Earnings Call Signals Cautious Turnaround

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has completed a $14 million placement of 73,68...

Paradigm Biopharmaceuticals Launches $2m Share Purchase Plan After $14m Placement

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an update. Paradigm Biopharmaceuticals reported continued momentum in its global Phase 3 tr...

Paradigm Hits 50% Dosing in Global Knee OA Trial and Bolsters Funding

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has announced a proposed securities purchase plan, un...

Paradigm Biopharmaceuticals Launches Securities Purchase Plan With Options Package

The latest announcement is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has outlined a proposed capital raising ...

Paradigm Biopharmaceuticals Plans Major Share and Option Issue to Boost Capital

An update from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals has completed a significantly upsized A$14 m...

Current Quarter	$0.34	Next Quarter	$0.36
Current Year	$1.62	Next Year	$1.76
QoQ Growth	+5.9%	YoY Growth	+8.6%
3Y EPS CAGR	+58.7%	Target Price	$16.74
Consensus	Buy	Upside	+8.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PBI	$15.42	+1.08%	876.31K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PBI	$15.42	+1.1%	876.31K
3
4
5
6

PBI

PBI

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Pitney Bowes Inc. Data in Excel

Get Pitney Bowes Inc. Data in Excel